Davies Ryan R, Russo Mark J, Hong Kimberly N, O'Byrne Michael L, Cork David P, Moskowitz Alan J, Gelijns Annetine C, Mital Seema, Mosca Ralph S, Chen Jonathan M
Division of Cardiothoracic Surgery, Children's Hospital of New York-Presbyterian and Columbia University College of Physicians and Surgeons, New York, New York 10032, USA.
J Thorac Cardiovasc Surg. 2008 Feb;135(2):421-7, 427.e1. doi: 10.1016/j.jtcvs.2007.09.048.
The use of mechanical circulatory support to bridge pediatric patients to cardiac transplantation presents unique challenges because of the difficult anatomy and physiology in these patients.
The United Network for Organ Sharing provided deidentifed patient-level data. The study population included 2532 transplantations performed on patients less than 19 years old in status 1/1A/1B between 1995 and 2005. Mechanical circulatory support was used in 431 patients: 241 (9.5%) received ventricular assist devices, 171 (6.8%) underwent extracorporeal membrane oxygenation, and 19 (0.8%) received intra-aortic balloon pumps.
Patients supported on ventricular assist devices had similar levels of hospitalization and intensive care use and less need for inotropic support (P < .0002) than had those not needing support. Five- and 10-year posttransplantation survival was better in patients receiving ventricular assist devices and patients not receiving mechanical circulatory support than in patients receiving extracorporeal membrane oxygenation or intra-aortic balloon pumping (P < .0001). Among mechanically supported patients, patients with a body surface area of less than 0.30 (odds ratio, 1.70; 95% confidence interval, 1.18-2.43) and those requiring extracorporeal membrane oxygenation (odds ratio, 1.65; 95% confidence interval, 1.15-2.35) or intra-aortic balloon pumping (odds ratio, 1.91; 95% confidence interval, 1.02-3.56) had higher long-term mortality. The use of a ventricular assist device at transplantation did not predict higher long-term, posttransplantation mortality.
Pediatric patients requiring a pretransplantation ventricular assist device have long-term survival similar to that of patients not receiving mechanical circulatory support. Early survival among patients undergoing extracorporeal membrane oxygenation and infants is poor, reinforcing the need for improvements in device design and physiologic management of infants and neonates.
由于小儿患者解剖结构和生理功能复杂,使用机械循环支持作为小儿心脏移植的过渡治疗面临独特挑战。
器官共享联合网络提供了去识别化的患者个体数据。研究人群包括1995年至2005年间在1/1A/1B状态下对19岁以下患者进行的2532例移植手术。431例患者使用了机械循环支持:241例(9.5%)接受了心室辅助装置,171例(6.8%)接受了体外膜肺氧合,19例(0.8%)接受了主动脉内球囊泵。
接受心室辅助装置支持的患者住院和重症监护使用水平相似,与不需要支持的患者相比,对血管活性药物支持的需求更少(P <.0002)。接受心室辅助装置的患者和未接受机械循环支持的患者移植后5年和10年生存率优于接受体外膜肺氧合或主动脉内球囊泵治疗的患者(P <.0001)。在接受机械支持的患者中,体表面积小于0.30的患者(优势比,1.70;95%置信区间,1.18 - 2.43)以及需要体外膜肺氧合(优势比,1.65;95%置信区间,1.15 - 2.35)或主动脉内球囊泵治疗的患者(优势比,1.91;95%置信区间,1.02 - 3.56)长期死亡率更高。移植时使用心室辅助装置并不能预测更高的移植后长期死亡率。
需要移植前心室辅助装置的小儿患者长期生存率与未接受机械循环支持的患者相似。接受体外膜肺氧合治疗的患者和婴儿的早期生存率较差,这凸显了改进婴儿和新生儿设备设计及生理管理的必要性。